Ligand id: 4981

Name: IL-15

Species: Human

1. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA. (1994)
Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.
J. Exp. Med., 180 (4): 1395-403. [PMID:7523571]
2. EMA. 
EU/3/16/1681: orphan designation- humanised monoclonal antibody targeting interleukin-15 for the treatment of eosinophilic oesophagitis.
Accessed on 11/01/2018. Modified on 11/01/2018.,
3. Finch DK, Midha A, Buchanan CL, Cochrane D, Craggs RI, Cruwys S, Grahames C, Kolbeck R, Lowe DC, Maltby J et al.. (2011)
Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo.
Br. J. Pharmacol., 162 (2): 480-90. [PMID:20942844]
4. Liu X, Kirk PB, Chang T, Charych DH. (2017)
Conjugates of an il-15 moiety and a polymer.
Patent number: US20170035898. Assignee: Nektar Therapeutics. Priority date: 03/04/2014. Publication date: 09/02/2017.
5. Quéméner A, Maillasson M, Arzel L, Sicard B, Vomiandry R, Mortier E, Dubreuil D, Jacques Y, Lebreton J, Mathé-Allainmat M. (2017)
Discovery of a Small-Molecule Inhibitor of Interleukin 15: Pharmacophore-Based Virtual Screening and Hit Optimization.
J. Med. Chem., 60 (14): 6249-6272. [PMID:28657314]
6. Vicari AP, Schoepfer AM, Meresse B, Goffin L, Léger O, Josserand S, Guégan N, Yousefi S, Straumann A, Cerf-Bensussan N et al.. (2017)
Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis.
MAbs, 9 (6): 927-944. [PMID:28581883]
7. Waldmann TA. (2006)
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.
Nat. Rev. Immunol., 6 (8): 595-601. [PMID:16868550]
8. Zhu X, Marcus WD, Xu W, Lee HI, Han K, Egan JO, Yovandich JL, Rhode PR, Wong HC. (2009)
Novel human interleukin-15 agonists.
J. Immunol., 183 (6): 3598-607. [PMID:19710453]